Literature DB >> 17372129

Moyamoya following cranial irradiation for primary brain tumors in children.

N J Ullrich1, R Robertson, D D Kinnamon, R M Scott, M W Kieran, C D Turner, S N Chi, L Goumnerova, M Proctor, N J Tarbell, K J Marcus, S L Pomeroy.   

Abstract

OBJECTIVE: To study the risk factors for the development of moyamoya syndrome after cranial irradiation for primary brain tumors in children.
METHODS: We reviewed neuroimaging studies and dosimetry data for 456 children who were treated with radiation for a primary brain tumor and who were prospectively evaluated with serial neuroimaging studies and neurologic evaluations. A total of 345 patients had both adequate neuroimaging and radiation dosimetry data for further analysis. We used survival analysis techniques to examine the relationship of clinically important variables as risk factors for the development of moyamoya over time.
RESULTS: Overall, 12 patients (3.5%) developed evidence of moyamoya. The onset of moyamoya was more rapid for patients with neurofibromatosis type 1 (NF1) (median of 38 vs 55 months) and for patients who received >5,000 cGy of radiation (median of 42 vs 67 months). In a multiple Cox proportional hazards regression analysis controlling for age at start of radiation, each 100-cGy increase in radiation dose increased the rate of moyamoya by 7% (hazard ratio [HR] = 1.07, 95% CI: 1.02 to 1.13, p = 0.01) and the presence of NF1 increased the rate of moyamoya threefold (HR = 3.07, 95% CI: 0.90 to 10.46, p = 0.07).
CONCLUSIONS: Moyamoya syndrome is a potentially serious complication of cranial irradiation in children, particularly for those patients with tumors in close proximity to the circle of Willis, such as optic pathway glioma. Patients who received higher doses of radiation to the circle of Willis and with neurofibromatosis type 1 have increased risk of the development of moyamoya syndrome.

Entities:  

Mesh:

Year:  2007        PMID: 17372129     DOI: 10.1212/01.wnl.0000257095.33125.48

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  67 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

3.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

4.  Whole-Genome Sequencing of Childhood Cancer Survivors Treated with Cranial Radiation Therapy Identifies 5p15.33 Locus for Stroke: A Report from the St. Jude Lifetime Cohort Study.

Authors:  Kevin R Krull; Yutaka Yasui; Yadav Sapkota; Yin Ting Cheung; Wonjong Moon; Kyla Shelton; Carmen L Wilson; Zhaoming Wang; Daniel A Mulrooney; Jinghui Zhang; Gregory T Armstrong; Melissa M Hudson; Leslie L Robison
Journal:  Clin Cancer Res       Date:  2019-08-28       Impact factor: 12.531

5.  Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation therapy.

Authors:  Sabine Mueller; Katherine Sear; Nancy K Hills; Nassim Chettout; Shervin Afghani; Erica Gastelum; Daphne Haas-Kogan; Heather J Fullerton
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-23       Impact factor: 7.038

6.  Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1.

Authors:  Smita Bhatia; Yanjun Chen; F Lennie Wong; Lindsey Hageman; Kandice Smith; Bruce Korf; Ashley Cannon; Daniel J Leidy; Alejandro Paz; Joseph E Andress; Gregory K Friedman; Katie Metrock; Joseph P Neglia; Michael Arnold; Lucie M Turcotte; Peter de Blank; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; D Wade Clapp; Kevin Shannon; Jean L Nakamura; Michael J Fisher
Journal:  J Clin Oncol       Date:  2019-09-18       Impact factor: 44.544

7.  Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future.

Authors:  Mohammed A Fouda; R Michael Scott; Karen J Marcus; Nicole Ullrich; Peter E Manley; Mark W Kieran; Liliana C Goumnerova
Journal:  Childs Nerv Syst       Date:  2019-07-10       Impact factor: 1.475

Review 8.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

9.  Headache as a risk factor for neurovascular events in pediatric brain tumor patients.

Authors:  Sarah M Kranick; Cynthia J Campen; Scott E Kasner; Sudha K Kessler; Robert A Zimmerman; Robert A Lustig; Peter C Phillips; Lauren A Beslow; Rebecca Ichord; Michael J Fisher
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

10.  Extended focal radiotherapy of 30 Gy alone for intracranial synchronous bifocal germinoma: a single institute experience.

Authors:  Pin-I Huang; Yi-Wei Chen; Tai-Tong Wong; Yi-Yen Lee; Kai-Ping Chang; Wan-Yuo Guo; Feng-Chi Chang; Muh-Lii Liang; Hsin-Hung Chen; Shi-Hwa Chiou; Sang-Hue Yen
Journal:  Childs Nerv Syst       Date:  2008-06-25       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.